Canada: Gilead Has Successfully Obtained A Declaration Of Invalidity Of A Patent That It Reasonably Expected Would Be Asserted Against It (Intellectual Property Weekly Abstracts Bulletin - Week Of November 9, 2015)

Last Updated: November 19 2015
Article by Chantal Saunders, Beverley Moore and Adrian J. Howard

Most Read Contributor in Canada, November 2017

Patent Infringement

Gilead has successfully obtained a declaration of invalidity of a patent that it reasonably expected would be asserted against it
Gilead Sciences Inc. v. Idenix Pharmaceuticals Inc., 2015 FC 1156
Drug: sofosbuvir

The Federal Court has allowed Gilead's claim to invalidate Idenix's '191 patent on the grounds of insufficient disclosure and lack of demonstrated utility/sound prediction. Idenix's counterclaim that Gilead's '657 Patent is invalid for anticipation was dismissed.

Idenix admitted that it did not test any of the compounds falling within the scope of the claims, so utility was assessed as a sound prediction. The parties agreed that the patent contains a promise that the compounds are useful in the treatment of Flaviviridae infections, including HCV infections, in humans and other hosts. The Court held that "treatment for a host infected with Hepatitis C virus" as requiring effectiveness in combination with low toxicity as measured in accordance with the therapeutic index. However, the Court also found that the '191 Patent makes no promise of any specific result or level of treatment. Thus, Gilead needed to prove that Idenix has not soundly predicted a scintilla of utility in the compounds for the treatment of Flaviviridae.

Ultimately, the Court found that Gilead has demonstrated that Idenix could not demonstrate, nor soundly predict as an inferred fact or prima facie reasonable inference, the utility of the 2'-C-Me/F nucleoside on June 27, 2003 as an effective treatment of Hepatitis C.

The Court held that the patentee is not required to disclose the basis for its sound prediction, but it would have failed if required to do so. The reason was because the '191 Patent relates to a sound prediction of a new composition, thus there is no utility disclosure requirement. The Court assumed that this exemption from disclosure applies both to the factual basis and the line of reasoning.

As to the allegation of insufficiency, the Court held that Gilead has established that the '191 Patent as supplemented by the common general knowledge does not sufficiently disclose how to synthesize the 2'-C-Me/F compound.

The Court summarized Gilead's novel overbreadth allegation as follows:

  • At the time the patent application was filed and published, Idenix had been unsuccessful in making a compound within the scope of the claims; as they did not have a way of making the claimed compounds, they cannot be said to have completed the act of invention; and
  • Not having invented the compounds, any claim to any such compounds is by definition overbroad.

In disagreeing with this novel claim of invalidity, the Court held that if the claims are soundly predicted and there has been sufficient disclosure of how to make the invention, then there can be no overbreadth of claims.

Idenix counterclaimed that Gilead's '657 Patent was anticipated by the disclosure and enablement of their subject matter by the '191 Patent. The Court found that there was disclosure of the invention, but no enabling disclosure of how to synthesize the compounds in the '191 Patent.

Idenix's infringement allegation was evaluated by the Court for the purpose of an appeal, even though the patent was found to be invalid. The Court held that Gilead's intermediate compound falls within the scope of the '191 Patent.

Idenix had further alleged that Gilead's '657 Patent is invalid pursuant to section 53 for knowingly omitting the name of an inventor, Dr. Stuyver. The Court ultimately held that he was not a co-inventor of the compound, nor did he sign a declaration under duress acknowledging this fact in 2005.

Other Cases of Interest

FCA Reinstates PMPRB Jurisdiction over Generic Companies with Permission from Patentee to Sell Medicine as they Enjoyed a Benefit from the Patent
Canada (Attorney General) v. Sandoz Canada Inc., 2015 FCA 249

In these cases, the government appealed Federal Court decisions that allowed judicial reviews of multiple PMPRB decisions. The issue on appeal was whether the Federal Court Judge properly held that Sandoz and ratiopharm fell outside the jurisdiction of the PMPRB, as they were not "patentees". The appeal was granted, as the FCA concluded that the PMPRB had properly interpreted "patentees" to include anyone obtaining a benefit from the patent.

Ratiopharm was granted an exclusive licence in Canada by GSK to sell ratio-salbutamol HFA, and indicated on its forms to Health Canada that it had GSK's permission to sell the product. Ratiopharm also sold a number of other products with the consent of the owner of the patents in question. Sandoz is a subsidiary of Novartis Canada. It sells a number of medicines covered by patents owned by Novartis Canada or one of its parent companies.

The FCA held that the PMPRB's decisions should be reviewed on the standard of reasonableness. In this case, the Federal Court judge had substituted his view of the legislation without considering whether the PMPRB's characterization met the threshold of acceptability and defensibility that separates reasonable and unreasonable decisions. Thus, the standard was misapplied. In this case, the FCA held the PMPRB's determination was a defensible interpretation of the Patent Act. The Federal Court judge focused on those in a position to cause excessive pricing rather than whether that mischief could be caused without the patent owner itself.

The FCA also held that it was not open to the Federal Court Judge to construe subsection 79(1) of the Patent Act narrowly on the basis that the PMPRB's construction might be unconstitutional. Furthermore, the PMPRB's adaption of its "ex-factory price" definition to include the situations with ratiopharm and Sandoz were not unreasonable. The FCA also held that the French text of subsection 79(1) does not give a different answer than the English text as to whether a "patentee" must also have the right to exclude others. The definition includes persons who exercise any rights in relation to a patent. The FCA rejected the concept that generic companies should be treated differently, as the term 'generic company' does not appear in the Patent Act. The FCA also dismissed the argument that s. 79(1) is unconstitutional.

Data Protection Regulations Apply When Comparison Added After NDS Filed
Hospira Healthcare Corporation v. Canada (Health), 2015 FC 1205
Drug: oxaliplatin

In this case, Hospira applied for judicial review of a decision of the Minister of Health, refusing to issue it a Notice of Compliance (NOC) for its drug oxaliplatin. The Minister had found that Hospira compared to Sanofi's innovative drug ELOXATIN oxaliplatin, and thus the data protection provisions of the Food and Drug Regulations applied. The Federal Court dismissed the application.

Oxaliplatin has been available in Canada through the special access program (SAP) since 1999. Hospira worked on a way to file a NDS from 2004-2006. However, it did not have clinical trial data, and could no longer ethically perform clinical trials, as it was already recognized by oncologists around the world as a 'standard of care' drug for colorectal cancer. After a number of unsatisfactory meetings with the Minister, Hospira filed a NDS on October 27, 2006. Sanofi also filed a NDS for oxaliplatin on November 20, 2006. The Sanofi NDS was given priority status.

Hospira's NDS was rejected at the screening stage as it only contained literature references; no pre-clinical or clinical data. Hospira judicially reviewed that decision, and it was sent back to the Minister for redetermination. Meanwhile, Sanofi obtained its NOC. It was granted data protection, and a 6-month paediatric extension. Hospira's NDS was deemed acceptable for examination in June 2011. However, a notice of non-compliance was issued in 2012. Hospira responded to the Minister's concerns, and was told that a DIN number would be assigned in October 2013. The executive summary recommending approval of the NOC did not contain a data protection assessment. When this was performed, Hospira was told that it could not receive its NOC due to Sanofi's data protection.

The Court held that the standard of correctness applies to the review of the Minister's decision. However, in this case, the decision was held to be both reasonable and correct. In answering the question of whether the Minister breached procedural fairness by failing to inform the applicant earlier in the approval process that the data protection provisions would apply, the Court held that this regulatory process is more akin to an administrative process, and, as such, the degree of procedural fairness owed is low. The question is whether the applicant knew the case it had to meet and was afforded an opportunity to respond. As Hospira waived its right to make written submissions in response to a letter from Health Canada, the Court rejected this ground of judicial review.

Hospira argued that Health Canada required addition of the comparisons to ELOXATIN oxaliplatin, and as such the original NDS did not seek an NOC on the basis of comparison. However, the Court held there was no basis for such a distinction in the Regulations. Post-filing amendments to the NDS are subject to the data protection provisions. Furthermore, this conclusion is confirmed by the purpose behind the data protection provisions, and to interpret the Regulations otherwise would run contrary to NAFTA and TRIPS.

Trademark Decisions

Dismissal of action relating to the alleged infringement of SPIRIT BEAR official marks upheld on appeal
Kitasoo First Nation v. Urban Distillers Inc., 2015 FCA 233

The Federal Court of Appeal has dismissed the appeal brought by the Kitasoo Band Council relating to a summary judgment motion brought in an action for infringement of their official mark SPIRIT BEAR. We previously summarized the Federal Court decision (2014 FC 833) that found the official marks were unenforceable and allowed the counterclaim by Urban Distillers. That holding essentially turned on a finding that the official marks were not shown to have been adopted and used as of the date of publication.

The Court of Appeal upheld the dismissal of the action, but overturned the holding relating to Urban Distillers' counterclaim because the counterclaim was not a part of the original summary judgment motion.

Other Industry News

Health Canada has published a Notice: Updates to the Guidance Document: Fees for the Review of Drug Submissions and Applications.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions